MIT has introduced BoltzGen, a generative AI model that can create novel protein binders aimed at addressing hard-to-treat diseases. This model builds on previous work with Boltz-2, which focused on predicting protein binding affinity. BoltzGen stands out by unifying protein design and structure prediction, allowing it to generate functional proteins that adhere to physical and chemical laws. The model has undergone extensive testing on 26 challenging targets, demonstrating its potential in drug development. Collaborators in the industry have expressed optimism about integrating BoltzGen into their platforms. The open-source nature of BoltzGen is expected to accelerate advancements in drug design, prompting a reevaluation of existing biotech offerings. Researchers believe that AI models like BoltzGen could revolutionize biomolecular design and therapeutic solutions.